Join to view full profile
1001 Partridge DrSte 100Ventura, CA 93003
Phone+1 805-485-8709
Fax+1 805-485-5521
Dr. Kong is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lynn Kong is an oncologist based in Ventura, CA, with advanced training in hematology and medical oncology from McGaw Medical Center at Northwestern University. She completed her medical degree at Northwestern University's Feinberg School of Medicine in 1991. Dr. Kong is the president of PMK Medical Group, a position she has held since 2008. Her clinical expertise includes breast cancer, melanoma, ovarian cancer and multiple myeloma. Dr. Kong has contributed to notable publications, including ASCO guidelines on opioid use in cancer pain and case reports on rare medical conditions. Her clinical trial involvement spans breast cancer, ovarian cancer and therapies for non-Hodgkin lymphoma. Her work has been recognized with CMS Meaningful Use Stage 1 and 2 Certifications.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1994 - 1997
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1991 - 1994
Northwestern University The Feinberg School of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1997 - 2028
IL State Medical License 1991 - 1999
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology- American college of physiciansFACP
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
- Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC Start of enrollment: 2016 Nov 30
- A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Start of enrollment: 2017 Jun 07
Publications & Presentations
PubMed
- 3 citationsNitrous Oxide Use Precipitates Pulmonary Embolism: A Case Report.Nancy Nguyen, Jessica Cao, Deborah Carlson, Lynn Kong, Graal Diaz
Cureus. 2024-09-01 - 15 citationsARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.Thomas J Herzog, John L Hays, Joyce N Barlin, Joseph Buscema, Noelle G Cloven
Future Oncology. 2023-07-01 - A Rare Case of Ruptured Appendicitis Secondary to Metastatic Ovarian Cancer.Alex G Raman, James Huynh, Kishan J Patel, Lynn R Kong, Brad D Barrows
The American Journal of Case Reports. 2023-02-22
Press Mentions
Putting in Longer Hours for World-Class CareJuly 11th, 2016
Professional Memberships
- Member
- Member
- Member
- Community Oncology AllianceMember
External Links
- Ventura County Hematology Oncology Specialistshttp://www.venturaoncology.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
